The contribution of white matter lesions to Parkinson's disease motor and gait symptoms: a critical review of the literature
Jazyk angličtina Země Rakousko Médium print-electronic
Typ dokumentu časopisecké články, přehledy
PubMed
26483133
DOI
10.1007/s00702-015-1470-9
PII: 10.1007/s00702-015-1470-9
Knihovny.cz E-zdroje
- Klíčová slova
- Cerebrovascular disease, Magnetic resonance imaging, Parkinson’s disease, White matter lesions,
- MeSH
- bílá hmota patologie MeSH
- cerebrovaskulární poruchy komplikace MeSH
- lidé MeSH
- neurologické poruchy chůze etiologie MeSH
- Parkinsonova nemoc komplikace patologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
White matter lesions (WML) associated with cerebrovascular disease (CVD) may be observed on magnetic resonance imaging in Parkinson's disease (PD) patients. WML are an important factor contributing to postural, gait, and cognitive impairment in the elderly without PD and worsening the course of Alzheimer's disease (AD). Numerous articles are available on this topic. Whether WML modify and negatively influence the clinical symptoms, and course of PD is a subject of debate. The aim of this review is to examine the available literature on the contribution of WML to PD motor symptoms in relation to clinical characteristics and methods of assessing WML on MRI. After reviewing the database, we identified 19 studies reporting the relationship between WML and PD; ten studies focusing on the impact of WML on the cognitive status in PD were excluded. We analysed altogether nine studies reporting the relationship between WML and motor signs of PD. The review found association between WML severity and freezing of gait, less significant to responsiveness to dopaminergic treatment and postural instability; no negative impact on tremor and falls was observed. The impact of WML on bradykinesia and rigidity was inconsistent. Comorbid WML is associated with worsening axial motor performance, probably independently from the degree of nigrostriatal dopaminergic denervation in PD. Reducing the vascular risk factors that cause WML may be helpful in preventing the development of axial symptoms and ultimately in improving the quality of life of patients with PD. Given the lack of systematic studies, additional research in this field is needed.
Department of Neurology Faculty Hospital Nitra Špitálska 6 949 01 Nitra Slovak Republic
Parkinson's Disease and Movement Disorders Unit IRCCS Fondazione Ospedale San Camillo Venice Italy
Zobrazit více v PubMed
Mov Disord. 2006 Jan;21(1):124-5 PubMed
Neuroepidemiology. 1994;13(3):108-12 PubMed
Stroke. 2002 Jan;33(1):21-5 PubMed
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed
Can J Neurol Sci. 2007 Feb;34(1):56-61 PubMed
Mov Disord. 2002 Jul;17(4):772-4 PubMed
Brain. 2013 Aug;136(Pt 8):2405-18 PubMed
Arch Neurol. 1995 Dec;52(12 ):1183-90 PubMed
Stroke. 2014 May;45(5):1531-8 PubMed
Ann Neurol. 1997 Jan;41(1):58-64 PubMed
Stroke. 1992 Jun;23(6):839-42 PubMed
Parkinsonism Relat Disord. 2015 Jul;21(7):692-7 PubMed
Arch Neurol. 1990 Feb;47(2):129-32 PubMed
Brain. 2011 Jan;134(Pt 1):73-83 PubMed
Nat Rev Neurol. 2015 Jun;11(6):319-26 PubMed
Lancet Neurol. 2011 Aug;10(8):734-44 PubMed
Mov Disord. 2005 Nov;20(11):1476-80 PubMed
Neurology. 2008 Mar 18;70(12):935-42 PubMed
Ann Neurol. 1990 Nov;28(5):597-613 PubMed
J Neurol Neurosurg Psychiatry. 2011 Feb;82(2):126-35 PubMed
AJR Am J Roentgenol. 1987 Aug;149(2):351-6 PubMed
Cerebrovasc Dis. 2008;25(3):247-53 PubMed
Eur J Neurol. 2012 Aug;19(8):1100-7 PubMed
Brain. 2011 Aug;134(Pt 8):2358-65 PubMed
AJNR Am J Neuroradiol. 1986 Jul-Aug;7(4):567-70 PubMed
Adv Exp Med Biol. 1984;180:545-54 PubMed
Nat Rev Neurosci. 2008 Nov;9(11):856-69 PubMed
J Neurol Sci. 2006 Oct 25;248(1-2):185-91 PubMed
Adv Neurol. 1996;69:293-303 PubMed
Neuroimage. 2009 Oct 1;47(4):2083-9 PubMed
Neurologia. 2014 May;29(4):218-23 PubMed
Parkinsonism Relat Disord. 2009 Jan;15(1):24-9 PubMed
Neuroimage. 2009 May 1;45(4):1151-61 PubMed
Clin Neurol Neurosurg. 1980;82(3):177-85 PubMed
Circulation. 2008 Feb 12;117(6):743-53 PubMed
Neurol Neurochir Pol. 2006 Jul-Aug;40(4):276-83 PubMed
Brain. 1999 Jul;122 ( Pt 7):1349-55 PubMed
Mov Disord. 1990;5(3):203-13 PubMed
Stroke. 2001 Jun;32(6):1318-22 PubMed
Parkinsonism Relat Disord. 2011 Sep;17(8):599-605 PubMed
Acta Neuropathol. 2003 May;105(5):415-9 PubMed
Rev Neurol (Paris). 1998 May;154(4):291-302 PubMed
J Appl Physiol (1985). 1987 Feb;62(2):791-7 PubMed
Stroke. 1990 Oct;21(10):1395-9 PubMed
Brain. 2011 Jan;134(Pt 1):59-72 PubMed
Mov Disord. 2012 Aug;27(9):1169-72 PubMed
Neuroimage. 2008 Jan 15;39(2):786-92 PubMed
J Aging Res. 2011;2011:391783 PubMed
Neurology. 2009 Nov 17;73(20):1670-6 PubMed
Mov Disord. 1997 Nov;12(6):1086-90 PubMed
Stroke. 2013 Apr;44(4):1147-9 PubMed
Neurol Clin. 1992 May;10(2):451-69 PubMed
JAMA. 2002 Jul 3;288(1):67-74 PubMed
Arch Neurol. 2010 Nov;67(11):1379-85 PubMed
Mov Disord. 2006 Nov;21(11):1990-4 PubMed
Mov Disord. 2006 Dec;21(12):2042-51 PubMed
Mov Disord. 2008 Aug 15;23 (11):1580-7 PubMed
Stroke. 1986 Nov-Dec;17(6):1084-9 PubMed
Neurology. 2014 Apr 29;82(17 ):1514-20 PubMed
Arch Neurol. 1999 Jan;56(1):98-102 PubMed
Stroke. 2011 Jul;42(7):2086-90 PubMed
Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):227-33 PubMed
Parkinsonism Relat Disord. 2010 Jan;16(1):31-5 PubMed
J Neuropathol Exp Neurol. 2010 May;69(5):442-8 PubMed
Age Ageing. 2006 Sep;35 Suppl 2:ii7-ii11 PubMed
Arch Gerontol Geriatr. 2009 Sep-Oct;49(2):255-9 PubMed
Handb Clin Neurol. 2007;84:417-25 PubMed
J Neurol Sci. 1993 Jan;114(1):7-12 PubMed
Acta Neurol Scand. 2011 Jan;123(1):41-7 PubMed
J Gerontol A Biol Sci Med Sci. 2004 Aug;59(8):818-26 PubMed
J Neurol. 2005 Sep;252(9):1045-9 PubMed
Stroke. 2003 Feb;34(2):441-5 PubMed
Neurology. 2001 Nov;57(10 Suppl 3):S11-26 PubMed
Parkinsonism Relat Disord. 2012 Jul;18(6):775-80 PubMed
PLoS One. 2013;8(1):e55193 PubMed
Yonsei Med J. 1998 Feb;39(1):50-5 PubMed
Mov Disord. 2010 Jan 15;25(1):50-6 PubMed
Mov Disord. 2013 Sep 15;28(11):1560-5 PubMed
Arch Neurol. 1995 Feb;52(2):191-4 PubMed
Ann Neurol. 2000 Feb;47(2):145-51 PubMed
Acta Neurol Scand. 2002 May;105(5):414-5 PubMed
J Neurol Sci. 2007 Jun 15;257(1-2):97-104 PubMed
Mov Disord. 2006 Feb;21(2):223-9 PubMed
Neurol Neurochir Pol. 2008 Nov-Dec;42(6):505-12 PubMed
Parkinsonism Relat Disord. 2013 Aug;19(8):761-3 PubMed
Neurology. 1994 Oct;44(10):1865-8 PubMed
Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13(4):226-31 PubMed
Brain Pathol. 2013 Mar;23(2):154-64 PubMed
Neurology. 1990 Oct;40(10):1529-34 PubMed
J Neurol. 2004 May;251(5):513-24 PubMed
Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S166-70 PubMed
Parkinsonism Relat Disord. 2013 Jul;19(7):680-3 PubMed
Neurodegener Dis. 2013;12(1):1-12 PubMed
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211 PubMed
Parkinsonism Relat Disord. 2009 Jan;15(1):64-7 PubMed
J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):545-7 PubMed
Cardiovasc Res. 1996 Oct;32(4):632-43 PubMed
Stroke. 2006 Mar;37(3):836-40 PubMed
Mov Disord. 2015 Jun;30(7):886-94 PubMed
Parkinsonism Relat Disord. 2015 Jul;21(7):704-8 PubMed
Mov Disord. 2003 Oct;18 Suppl 7:S43-51 PubMed
White matter alterations in Parkinson's disease with normal cognition precede grey matter atrophy